“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Specific proposals and targets top the universities’ desired priorities

What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

Kennedy attackerar dansk vaccinstudie – ”Propagandanummer från läkemedelsindustrin”

USA:s hälsominister Robert F. Kennedy Jr. uppmanar en medicinsk tidskrift att dra tillbaka publiceringen av en stor vaccinstudie, vars slutsatser han ogillar. M...

How to avoid measurement inaccuracies due to wear

Expert tip from ZEISS.

My Moberg blir ny direktör på Läkemedelsverket

My Moberg tar över rollen som direktör för verksamhetsområdet tillstånd hos Läkemedelsverket.

Miljonregn över ”excellenta” inkubatorer

Det står nu klart vilka svenska inkubatorer som klassas som excellenta och får dela på totalt nästan 400 miljoner kronor i stöd från innovationsmyndigheten Vinn...

Tyska Biontech storsatsar i Storbritannien

Den tyska vaccin- och läkemedelsutvecklaren Biontech ska investera upp till en miljard pund, motsvarande nästan 13 miljarder kronor, på att utveckla sin forskni...

Danska läkemedelsfonder investerar i talangfabrik

Novo Nordisk Foundation, Lundbeck Foundation och Leo Foundation investerar 123 miljoner danska kronor, motsvarande omkring 188 miljoner svenska kronor, i ett ny...

Virology professor on the threat from X: ”The next pandemic could be worse“

The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...

Aurevia

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which...

Anna Törner: “My quantified life”

“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the mor...

Attendo värvar toppchef internt

Attendos affärsområdeschef väljer att lämna rollen efter bara ett år. Nu rekryteras en ny chef internt som har arbetat inom bolaget i snart två decennier.

Ett steg närmare vaccin mot klamydia – Sanofi får snabbspår

Franska läkemedelsföretaget Sanofi får snabbspårsstatus i USA för sin mRNA-vaccinkandidat som ska förebygga klamydia.

Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?

In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

A+ Science AB

Anna Törner: The minute between life and death

“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...

ProPharma

Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”

It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...

Astra Zeneca fryser miljardinvestering i Storbritannien

Astra Zeneca har pausat en planerad investering på motsvarande 2,5 miljarder kronor. Det är det senaste läkemedelsbolaget som drar tillbaka sina satsningar i Storbritannien.